SCOTLAND’S Omega Diagnostics has seen a 455% surge in interest since March 23 as private investors have swarmed around biotech, pharmaceutical and healthcare stocks during lockdown.

According to shares website ADVFN, AIM-listed Omega is second only to Manchester’s Genedrive in generating new followers tracking company information during the past three months. Genedrive, which has developed two coronavirus tests, has seen a 1,400% increase in followers since the start of lockdown.

READ MORE: Omega Diagnostics surges as virus testing plans progress

Headquartered in Alva, Omega Diagnostics is part of the UK Rapid Test Consortium (UK-RTC) that is developing an at-home test kit for Covid19. The UK-RTC is led by York-based Abingdon Health, which said earlier this month that the partners expect to reach design freeze in June.

Omega is also involved in a second partnership with Bedfordshire-based Mologic to develop a laboratory test for Covid19 antibodies. Omega is making the tests from raw materials supplied by Mologic.

The partners announced last week that they have taken their first order for the laboratory test, a £100,000 shipment that will be sent to Senegal. Registration and evaluation activities are currently taking place in 15 countries, which is expected to lead to more orders soon.